Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5671553 | Clinical Microbiology and Infection | 2016 | 7 Pages |
Abstract
In recent years a revolution in hepatitis C virus drug development has taken place from troublesome regimens with pegylated interferon-alfa for 24 to 48Â weeks with limited success to all-oral single tablet regimens taken for 12Â weeks with very high chances of success. These promising results are not available to everybody. Depending on, for example, geographical factors with limited availability of new compounds, virus factors like hepatitis C virus genotype and host factors like presence of cirrhosis, these favorable outcomes can be compromised. This review discusses the recent clinical trials (from phase 3 registration through real-world application), highlighting the different available regimens and their success rates.
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
Authors
J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman, the European Study Group for Viral Hepatitis (ESGVH) the European Study Group for Viral Hepatitis (ESGVH),